The GM1 Gangliosidosis Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the GM1 Gangliosidosis Market?
The size of the GM1 gangliosidosis market has experienced significant growth in recent years. The market increased from $0.51 billion in 2024 to $0.57 billion in 2025, with a compound annual growth rate (CAGR) of 11.4%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the GM1 Gangliosidosis Industry?
The GM1 gangliosidosis market is predicted to reach $0.87 billion in 2029, with a compound annual growth rate (CAGR) of 11.1%.
Download Your Free Sample of the 2025 GM1 Gangliosidosis Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the GM1 Gangliosidosis Market?
The key drivers in the gm1 gangliosidosis market are:
• Increase in GM1 gangliosidosis cases and lysosomal storage disorders
• Rise in the number of clinical trials focused on this condition
• Emphasis on gene therapy and editing to combat the disease
• Increased adoption of genetic screening programs and advancements in personalized medicine
Global Market Segmentation: Identifying Major GM1 Gangliosidosis Industry Segments
The GM1 gangliosidosis market covered in this report is segmented –
1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis
2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy
3) By End-User: Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset
2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset
3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset
Pre-order the 2025 GM1 Gangliosidosis Global Market Report for Fast Delivery & Comprehensive Insights!
What are the emerging Trends Shaping the Future of the GM1 Gangliosidosis Market?
The key trends in the gm1 gangliosidosis market are:
• The future of the GM1 Gangliosidosis market is being shaped by advancements in gene-editing technologies.
• The integration of technology within the healthcare sector is an emerging trend.
• The market is witnessing advancement in diagnostic techniques.
• There is a noticeable trend towards developing advanced formulations and enhanced genetic therapies.
Who Are the Top Competitors & Leading Players in the GM1 Gangliosidosis Market?
Major players in the gm1 gangliosidosis market are:
• Pfizer Inc.
• Sanofi S.A.
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Sarepta Therapeutics Inc.
• CRISPR Therapeutics AG
• REGENXBIO Inc.
• Passage Bio Inc.
• Orchard Therapeutics plc
• AVROBIO Inc.
• uniQure N.V.
• GEMMA Biotherapeutics Inc.
• Lysogene S.A.
• AZAFAROS B.V.
• BioStrategies LC
• Sio Gene Therapies Inc.
• Gain Therapeutics Inc.
• Dorphan S.A.
• bluebird bio Inc.
• Axovant Gene Therapies Ltd.
• SphinCS GmbH.
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the GM1 gangliosidosis market in 2024
